JP2011523952A5 - - Google Patents

Download PDF

Info

Publication number
JP2011523952A5
JP2011523952A5 JP2011512478A JP2011512478A JP2011523952A5 JP 2011523952 A5 JP2011523952 A5 JP 2011523952A5 JP 2011512478 A JP2011512478 A JP 2011512478A JP 2011512478 A JP2011512478 A JP 2011512478A JP 2011523952 A5 JP2011523952 A5 JP 2011523952A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
same
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011512478A
Other languages
English (en)
Japanese (ja)
Other versions
JP5820722B2 (ja
JP2011523952A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/003411 external-priority patent/WO2010002428A2/en
Publication of JP2011523952A publication Critical patent/JP2011523952A/ja
Publication of JP2011523952A5 publication Critical patent/JP2011523952A5/ja
Application granted granted Critical
Publication of JP5820722B2 publication Critical patent/JP5820722B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011512478A 2008-06-06 2009-06-05 シクロスポリン類似体及びhcv感染の治療におけるその使用 Expired - Fee Related JP5820722B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5964908P 2008-06-06 2008-06-06
US61/059,649 2008-06-06
PCT/US2009/003411 WO2010002428A2 (en) 2008-06-06 2009-06-05 Novel macrocyclic peptides

Publications (3)

Publication Number Publication Date
JP2011523952A JP2011523952A (ja) 2011-08-25
JP2011523952A5 true JP2011523952A5 (enExample) 2012-07-26
JP5820722B2 JP5820722B2 (ja) 2015-11-24

Family

ID=41415358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512478A Expired - Fee Related JP5820722B2 (ja) 2008-06-06 2009-06-05 シクロスポリン類似体及びhcv感染の治療におけるその使用

Country Status (6)

Country Link
US (1) US9090671B2 (enExample)
EP (1) EP2280989B1 (enExample)
JP (1) JP5820722B2 (enExample)
CN (1) CN102083852A (enExample)
CA (1) CA2724523A1 (enExample)
WO (1) WO2010002428A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1802650T1 (sl) * 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
CA2623864C (en) 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びhcv感染の治療におけるその使用
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
WO2012103520A1 (en) 2011-01-28 2012-08-02 Board Of Regents Of The University Of Nebraska Methods and compositions for modulating cyclophilin d
CA2874548A1 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
CN109485771A (zh) * 2018-10-30 2019-03-19 焦作中维特品药业股份有限公司 一种交联聚维酮的制备方法
JP7277222B2 (ja) 2019-03-29 2023-05-18 出光興産株式会社 潤滑油組成物
CA3152922A1 (en) * 2019-10-12 2021-04-15 Michael Peel Treatment and prevention of nephrotoxin-induced kidney injuries
CN114230498B (zh) * 2021-12-30 2023-11-17 湖北华世通生物医药科技有限公司 β-(二甲氨基)乙基对甲苯磺酸巯酯盐酸盐的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US496193A (en) * 1893-04-25 Hot-air furnace
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
DE69124459T3 (de) 1990-11-02 2001-05-31 Novartis Ag, Basel Zyklosporine
US5948693A (en) 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
NZ315324A (en) 1995-07-17 1999-10-28 Chem Ag C Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (ja) 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
GB9811854D0 (en) 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
WO1999065933A1 (en) 1998-06-12 1999-12-23 C-Chem Ag Novel cyclosporins
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
USRE40987E1 (en) 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
US6521595B1 (en) 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
US7015499B1 (en) * 1999-12-01 2006-03-21 D-Wave Systems, Inc. Permanent readout superconducting qubit
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
CZ303213B6 (cs) 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
KR100718371B1 (ko) 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 3-β-D-리보푸라노실티아졸로[4,5-d]피리디민누클레오시드 및 이의 용도
US6987090B2 (en) 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
JP2005533777A (ja) 2002-06-17 2005-11-10 メルク エンド カムパニー インコーポレーテッド Rna抗ウイルス剤としての炭素環ヌクレオシドアナログ
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
WO2004007512A2 (en) 2002-07-16 2004-01-22 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
EP1765330A4 (en) 2004-03-01 2007-10-17 Viropharma Inc PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
GB0413087D0 (en) 2004-06-11 2004-07-14 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5080973B2 (ja) 2004-06-24 2012-11-21 メルク・シャープ・エンド・ドーム・コーポレイション Rna依存性rnaウイルスの感染を処置するためのヌクレオシドアリールホスホルアミダート
CN1984670A (zh) * 2004-07-13 2007-06-20 诺瓦提斯公司 治疗阿尔茨海默病的环孢菌素
JP2008506648A (ja) 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト C型肝炎(hcv)処置のためのシクロスポリンとペグ化インターフェロンの組合せ剤の使用
GB0416396D0 (en) 2004-07-22 2004-08-25 Angeletti P Ist Richerche Bio Therapeutic agents
AP2313A (en) 2004-08-18 2011-10-31 Pfizer Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.
SI1802650T1 (sl) 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
ZA200703157B (en) * 2004-10-01 2008-08-27 Scynexis Inc 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
PT1793844E (pt) 2004-10-01 2011-03-10 Debiopharm Sa Utilização de [d-meala]3-[etval]4-csa para o tratamento de infecção causada pelo vírus da hepatite c
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US20080280842A1 (en) 2004-10-21 2008-11-13 Merck & Co., Inc. Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
EP1807397A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
US7897565B2 (en) 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment
RU2007128098A (ru) 2004-12-23 2009-01-27 Новартис АГ (CH) Соединения для лечения инфекций, вызываемых вирусами семейства flaviviridae
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
CN105169369B (zh) 2005-09-30 2019-10-18 中美华世通生物医药科技(武汉)有限公司 治疗和预防丙型肝炎感染的方法和药物组合物
CA2623864C (en) 2005-09-30 2014-12-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びhcv感染の治療におけるその使用
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
AU2010203660A1 (en) 2009-01-07 2011-07-28 Scynexis, Inc Combination of a cyclosporine derivative and nucleosides for treating HCV
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽

Similar Documents

Publication Publication Date Title
JP2011523952A5 (enExample)
JP2010518128A5 (enExample)
JP2009143956A5 (enExample)
JP2011509949A5 (enExample)
NZ593712A (en) Intermediates for synthesising nucleoside aryl phosphoramidates
JP2013523896A5 (enExample)
JP2015537020A5 (enExample)
RU2017121906A (ru) Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии
JP2005533040A5 (enExample)
JP2013545818A5 (enExample)
JP2010500293A5 (enExample)
JP2009507909A5 (enExample)
JP2013508279A5 (enExample)
JP2017523169A5 (enExample)
JP2012505871A5 (enExample)
JP2013523897A5 (enExample)
JP2017537940A5 (enExample)
JP2005523922A5 (enExample)
JP2011509309A5 (enExample)
JP2014528467A5 (enExample)
JP2008504265A5 (enExample)
JP2011513410A5 (enExample)
JP2010031025A5 (enExample)
JP2014521688A5 (enExample)
JP2009523760A5 (enExample)